Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib Maintenance in NDMM (China Continuation)
NCT03748953Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ixazomib in multiple myeloma (MM), sponsored by Millennium Pharmaceuticals. Primary endpoints: Number of Participants Categorized According to Performance Status (PS) Based on Eastern Cooperative Oncology Group (ECOG) PS at Month 25, Percentage of Participants Receiving Ixazomib With Treatment-emergent Adverse Events (TEAEs) up to 58.4 months and 2 more. Started Jan 2019; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03748953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748953.